Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Cuprina Holdings (Nasdaq: CUPR) received a Nasdaq noncompliance notice dated November 26, 2025 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cuprina Holdings (Nasdaq: CUPR) received a Nasdaq noncompliance notice dated November 26, 2025 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5550(a)(2).
Cuprina has an initial 180-calendar-day compliance period to regain the $1.00 closing bid for at least ten consecutive business days. If not regained, the company may be eligible for a second 180-day period by meeting market value and other initial listing standards (excluding the bid price) and providing written notice to cure, potentially by effecting a reverse stock split. Shares will continue to trade uninterrupted under the symbol CUPR while the process unfolds. Cuprina is evaluating options to regain compliance but stated there is no assurance it will do so.
Positive
- Nasdaq notice dated Nov 26, 2025
- Initial 180-calendar-day compliance period
- Requirement: $1.00 closing bid for 10 consecutive business days
- Shares continue trading under CUPR
Negative
- Currently noncompliant with Nasdaq $1.00 minimum bid
- Risk of delisting if deficiency is not cured within compliance periods
- May need a reverse stock split to regain compliance
- Company states no assurance it will regain compliance
Details
News Market Reaction – CUPR
On Nov 28, the day this news came out, CUPR closed 1.47% above the previous close.
Data tracked by StockTitan Argus for the Nov 28 session.
Key Figures
- Minimum bid requirement
- $1 per share
- Nasdaq Listing Rule 5550(a)(2) continued listing standard
- Noncompliance window
- 30 business days
- Period of sub-$1 closing bid triggering Nasdaq notice
- Initial compliance period
- 180 calendar days
- Time allowed to regain Nasdaq minimum bid compliance
- Required compliant streak
- 10 business days
- Minimum stretch with ≥$1 closing bid to cure deficiency
- Additional compliance period
- 180 calendar days
- Potential second period if other Nasdaq standards are met
- Current share price
- $0.495
- Before publication of Nasdaq deficiency notice release
- 52-week high
- $9.50
- Pre-news 52-week peak price level
- 52-week low
- $0.55
- Pre-news 52-week low compared with current price below this level
Historical Context
-
Weak revenue and net loss with 2026 initiatives outlined.
-
Nasdaq notice for failing to meet $1.00 minimum bid requirement.
-
Joint venture for novel iodine-based antiseptic wound care products.
-
MOU to integrate medical waste recycling into a Singapore facility.
-
Announcement of participation in Skyline Signature Series investor event.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rules 5550(a)(2) regulatory
minimum bid price financial
nasdaq capital market regulatory
reverse stock split financial
delisting regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina’s closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of
However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days in which to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s security is at least
In the event the Company does not regain compliance, Cuprina may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If the Cuprina meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that its securities will be subject to delisting.
The Nasdaq notification letter does not result in the immediate delisting of the Company's ordinary shares, and the shares will continue to trade uninterrupted under the symbol "CUPR."
Cuprina is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although Cuprina will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
About Cuprina Holdings (Cayman) Limited
We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https:// www.cuprina.com.
FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg
Investor Relations Inquiries:
Skyline Corporate Communications Group, LLC
Scott Powell, President
1177 Avenue of the Americas, 5th Floor
New York, New York 10036
Office: (646) 893-5835
Email: info@skylineccg.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.